What is Actinium Pharmac's earnings per share (EPS)?

Actinium Pharmac (ATNM) reported diluted earnings per share of $-1.09 for fiscal year 2025. This represents a 14.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Actinium Pharmac Financials

ATNM

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Actinium Pharmac (ATNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 25 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATNM FY2025 2026-04-22

Actinium’s core mechanic is financing research losses with cash, while FY2025 spending cuts only slowed equity erosion.

FY2025 free cash burn improved to -$24.7M from -$33.1M, but the relief came from a smaller R&D budget rather than revenue expansion. Because financing cash flow swung from a $29.3M inflow in FY2024 to roughly $0 in FY2025, the business stopped offsetting burn with fresh capital and let that burn pass through to the balance sheet.

The company still has near-term liquidity: cash of $48.0M against current liabilities of $8.0M suggests upcoming obligations are covered. But solvency has tightened, because liabilities now make up most of the asset base after several years of losses reduced equity to a thin cushion.

This is an operating-expense burn story, not an asset-build story: capital spending was only $104K while free cash flow was -$24.7M. That means cash use is driven mainly by research and corporate overhead, so the business behaves more like a funded development program than a scaled commercial operation.

Financial Health Signals

Financial Profile 24/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Actinium Pharmac's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Actinium Pharmac has an operating margin of -40274.4%, meaning the company retains $-40274 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

Actinium Pharmac has elevated debt relative to equity (D/E of 5.61), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

100

With a current ratio of 6.20, Actinium Pharmac holds $6.20 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Actinium Pharmac generated -$24.6M in operating cash flow, capex of $104K consumed most of it, leaving -$24.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Actinium Pharmac generates a -432.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -116.7% the prior year.

Piotroski F-Score Weak

2/9

Actinium Pharmac passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.73x

For every $1 of reported earnings, Actinium Pharmac generates $0.73 in operating cash flow (-$24.6M OCF vs -$33.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$90K

Actinium Pharmac generated $90K in revenue in fiscal year 2025.

EBITDA

-$36.1M

YoY+14.0%

Actinium Pharmac's EBITDA was -$36.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.0% from the prior year.

Net Income

-$33.9M

YoY+11.4%

Actinium Pharmac reported -$33.9M in net income in fiscal year 2025. This represents an increase of 11.4% from the prior year.

EPS (Diluted)

$-1.09

YoY+14.2%

Actinium Pharmac earned $-1.09 per diluted share (EPS) in fiscal year 2025. This represents an increase of 14.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$24.7M

YoY+25.4%

Actinium Pharmac generated -$24.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 25.4% from the prior year.

Cash & Debt

$48.0M

YoY-34.2%

5Y CAGR-5.5%

10Y CAGR+6.5%

Actinium Pharmac held $48.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

31M

YoY+0.0%

5Y CAGR+12.2%

Actinium Pharmac had 31M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-40274.4%

Actinium Pharmac's operating margin was -40274.4% in fiscal year 2025, reflecting core business profitability.

Net Margin

-37652.2%

Actinium Pharmac's net profit margin was -37652.2% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

-432.6%

YoY-315.8pp

5Y CAGR-396.3pp

10Y CAGR-336.9pp

Actinium Pharmac's ROE was -432.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 315.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$21.1M

YoY-29.7%

5Y CAGR+5.6%

10Y CAGR+4.6%

Actinium Pharmac invested $21.1M in research and development in fiscal year 2025. This represents a decrease of 29.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$104K

YoY+845.5%

5Y CAGR-16.3%

10Y CAGR+8.1%

Actinium Pharmac invested $104K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 845.5% from the prior year.

ATNM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$90K	N/A	$81K-92.1%	$1.0M-10.0%	$1.1M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$900K	N/A
Gross Profit	N/A	N/A	N/A	N/A	$244K	N/A
R&D Expenses	$21.1M-29.7%	$30.0M-22.3%	$38.7M+67.1%	$23.1M+28.3%	$18.0M+12.1%	$16.1M
SG&A Expenses	$15.2M+26.0%	$12.1M-9.4%	$13.3M+11.1%	$12.0M+48.6%	$8.1M+28.0%	$6.3M
Operating Income	-$36.2M+13.9%	-$42.1M+18.9%	-$51.9M-52.2%	-$34.1M-36.6%	-$25.0M-11.5%	-$22.4M
Interest Expense	N/A	N/A	$3.1M+185.4%	$1.1M+472.1%	$190K+6.7%	$178K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$33.9M+11.4%	-$38.2M+21.7%	-$48.8M-47.9%	-$33.0M-33.3%	-$24.8M-11.5%	-$22.2M
EPS (Diluted)	$-1.09+14.2%	$-1.27+30.6%	$-1.83-33.6%	$-1.37-14.2%	$-1.20	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	$90K	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.2M	N/A	$4.2M-12.9%	$4.9M-36.6%	$7.7M	N/A	$9.8M+10.8%	$8.8M
SG&A Expenses	$1.7M	N/A	$1.5M-41.5%	$2.6M-70.6%	$8.9M	N/A	$2.8M-21.3%	$3.6M
Operating Income	-$5.9M	N/A	-$5.7M+24.1%	-$7.5M+54.9%	-$16.6M	N/A	-$12.6M-1.5%	-$12.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.5M	N/A	-$5.1M+25.4%	-$6.9M+56.8%	-$15.9M	N/A	-$11.6M-1.9%	-$11.4M
EPS (Diluted)	$-0.18	N/A	$-0.16+27.3%	$-0.22+56.9%	$-0.51	N/A	$-0.37+2.6%	$-0.38

ATNM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$51.8M-32.7%	$76.9M-5.6%	$81.4M-28.7%	$114.2M+42.1%	$80.4M+21.1%	$66.4M
Current Assets	$49.4M-33.7%	$74.5M-4.8%	$78.3M-29.5%	$110.9M+39.1%	$79.7M+22.8%	$64.9M
Cash & Equivalents	$48.0M-34.2%	$72.9M-4.9%	$76.7M-29.6%	$108.9M+39.9%	$77.8M+22.4%	$63.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$43.9M-0.5%	$44.1M-2.1%	$45.1M-5.5%	$47.7M+597.2%	$6.8M+34.8%	$5.1M
Current Liabilities	$8.0M-2.2%	$8.1M-4.1%	$8.5M-20.1%	$10.6M+55.4%	$6.8M+43.5%	$4.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.8M-76.1%	$32.8M-10.0%	$36.4M-45.3%	$66.5M-9.6%	$73.5M+19.9%	$61.3M
Retained Earnings	-$409.7M-9.0%	-$375.8M-11.3%	-$337.6M-16.9%	-$288.8M-12.9%	-$255.7M-10.7%	-$231.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$45.4M-12.2%	$51.8M-7.8%	$56.2M-10.9%	$63.0M-8.2%	$68.6M-10.7%	$76.9M-6.4%	$82.1M-8.6%	$89.9M
Current Assets	$43.3M-12.4%	$49.4M-9.2%	$54.4M-10.9%	$61.0M-8.2%	$66.5M-10.8%	$74.5M-6.3%	$79.5M-8.7%	$87.1M
Cash & Equivalents	$42.1M-12.2%	$48.0M-10.1%	$53.4M-10.9%	$59.9M-8.3%	$65.3M-10.4%	$72.9M-7.3%	$78.7M-8.6%	$86.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$43.1M-1.8%	$43.9M+3.7%	$42.4M-3.7%	$44.0M+2.4%	$43.0M-2.7%	$44.1M+0.5%	$43.9M-4.6%	$46.0M
Current Liabilities	$7.3M-7.8%	$8.0M+16.6%	$6.8M-17.8%	$8.3M+16.9%	$7.1M-12.7%	$8.1M+5.1%	$7.8M-20.3%	$9.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.3M-70.6%	$7.8M-43.2%	$13.8M-27.5%	$19.0M-26.0%	$25.7M-21.6%	$32.8M-14.3%	$38.2M-12.8%	$43.8M
Retained Earnings	-$415.2M-1.3%	-$409.7M-1.5%	-$403.8M-1.3%	-$398.6M-1.8%	-$391.8M-4.2%	-$375.8M-1.8%	-$369.2M-3.2%	-$357.6M

ATNM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$24.6M+25.7%	-$33.1M+30.1%	-$47.3M-647.6%	$8.6M+141.4%	-$20.9M+3.5%	-$21.6M
Capital Expenditures	$104K+845.5%	$11K-92.8%	$153K-58.2%	$366K+175.2%	$133K-47.4%	$253K
Free Cash Flow	-$24.7M+25.4%	-$33.1M+30.3%	-$47.5M-673.7%	$8.3M+139.4%	-$21.0M+4.0%	-$21.9M
Investing Cash Flow	-$104K-845.5%	-$11K+92.8%	-$153K+58.2%	-$366K-175.2%	-$133K+47.4%	-$253K
Financing Cash Flow	-$217K-100.7%	$29.3M+97.2%	$14.9M-35.7%	$23.1M-34.4%	$35.2M-53.8%	$76.2M
Dividends Paid	N/A	N/A	N/A	$0	$0	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$5.9M-11.0%	-$5.3M+16.4%	-$6.3M-17.3%	-$5.4M+28.8%	-$7.6M-31.7%	-$5.8M+52.0%	-$12.0M-50.2%	-$8.0M
Capital Expenditures	$2K	N/A	N/A	N/A	N/A	$0	$0	$0
Free Cash Flow	-$5.9M	N/A	N/A	N/A	N/A	-$5.8M+52.0%	-$12.0M-50.2%	-$8.0M
Investing Cash Flow	-$2K	N/A	N/A	N/A	N/A	$0	$0	$0
Financing Cash Flow	-$3K0.0%	-$3K+98.6%	-$209K-6866.7%	-$3K-50.0%	-$2K+33.3%	-$3K-100.1%	$4.6M-53.8%	$10.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATNM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	21.3%	N/A
Operating Margin	-40274.4%	N/A	-64098.8%-60787.7pp	-3311.1%-1128.9pp	-2182.2%	N/A
Net Margin	-37652.2%	N/A	-60269.1%-57063.6pp	-3205.5%-1040.0pp	-2165.6%	N/A
Return on Equity	-432.6%-315.8pp	-116.7%+17.5pp	-134.2%-84.5pp	-49.7%-16.0pp	-33.7%+2.5pp	-36.2%
Return on Assets	-65.5%-15.7pp	-49.7%+10.2pp	-59.9%-31.0pp	-28.9%+1.9pp	-30.8%+2.6pp	-33.5%
Current Ratio	6.20-2.9	9.14-0.1	9.21-1.2	10.44-1.2	11.66-2.0	13.62
Debt-to-Equity	5.61+4.3	1.35+0.1	1.24+0.5	0.72+0.6	0.09+0.0	0.08
FCF Margin	-27426.7%	N/A	-58627.2%-59430.8pp	803.7%+2639.3pp	-1835.6%	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-6324.4%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	-5701.1%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-239.7%	N/A	-37.2%-1.0pp	-36.2%+25.8pp	-62.0%	N/A	-30.3%-4.4pp	-25.9%
Return on Assets	-12.2%	N/A	-9.1%+1.8pp	-10.9%+12.3pp	-23.2%	N/A	-14.1%-1.5pp	-12.6%
Current Ratio	5.89-0.3	6.20-1.8	7.96+0.6	7.34-2.0	9.35+0.2	9.14-1.1	10.25+1.3	8.95
Debt-to-Equity	18.72+13.1	5.61+2.5	3.07+0.8	2.31+0.6	1.67+0.3	1.35+0.2	1.15+0.1	1.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Pds Biotechnology Corporation PDSB

$64.7M

Polypid Ltd. PYPD

$92.6M

Vtv Therapeutics VTVT

$139.8M

Genenta Science Spa GNTA

$13.9M

Cue Biopharma Inc CUE

$81.3M

Frequently Asked Questions

What is Actinium Pharmac's annual revenue?

Actinium Pharmac (ATNM) reported $90K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Actinium Pharmac profitable?

No, Actinium Pharmac (ATNM) reported a net income of -$33.9M in fiscal year 2025, with a net profit margin of -37652.2%.

What is Actinium Pharmac's EBITDA?

Actinium Pharmac (ATNM) had EBITDA of -$36.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Actinium Pharmac's operating margin?

Actinium Pharmac (ATNM) had an operating margin of -40274.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Actinium Pharmac's net profit margin?

Actinium Pharmac (ATNM) had a net profit margin of -37652.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Actinium Pharmac's return on equity (ROE)?

Actinium Pharmac (ATNM) has a return on equity of -432.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Actinium Pharmac's free cash flow?

Actinium Pharmac (ATNM) generated -$24.7M in free cash flow during fiscal year 2025. This represents a 25.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Actinium Pharmac's operating cash flow?

Actinium Pharmac (ATNM) generated -$24.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Actinium Pharmac's total assets?

Actinium Pharmac (ATNM) had $51.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Actinium Pharmac's capital expenditures?

Actinium Pharmac (ATNM) invested $104K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Actinium Pharmac spend on research and development?

Actinium Pharmac (ATNM) invested $21.1M in research and development during fiscal year 2025.

How many shares does Actinium Pharmac have outstanding?

Actinium Pharmac (ATNM) had 31M shares outstanding as of fiscal year 2025.

What is Actinium Pharmac's current ratio?

Actinium Pharmac (ATNM) had a current ratio of 6.20 as of fiscal year 2025, which is generally considered healthy.

What is Actinium Pharmac's debt-to-equity ratio?

Actinium Pharmac (ATNM) had a debt-to-equity ratio of 5.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Actinium Pharmac's return on assets (ROA)?

Actinium Pharmac (ATNM) had a return on assets of -65.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Actinium Pharmac's cash runway?

Based on fiscal year 2025 data, Actinium Pharmac (ATNM) had $48.0M in cash against an annual operating cash burn of $24.6M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Actinium Pharmac's Piotroski F-Score?

Actinium Pharmac (ATNM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Actinium Pharmac's earnings high quality?

Actinium Pharmac (ATNM) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Actinium Pharmac?

Actinium Pharmac (ATNM) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.